SCARA3: A Potential Drug Target and Biomarker (G51435)

Target Name: SCARA3

NCBI ID: G51435

SCARA3

SCARA3: A Potential Drug Target and Biomarker

Scavenger receptor class A member 3 (ISOform 1) is a protein that is expressed in various tissues throughout the body. It is a member of the scavenger receptor family, which is a subfamily of the superfamily of G-coupled receptors. Scavenger receptors are involved in the immune response and have been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified SCARA3 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will review the current literature on SCARA3 and its potential as a drug target and biomarker.

Potential Drug Target

SCARA3 has been identified as a potential drug target due to its involvement in the immune response and its expression in various tissues. Studies have shown that SCARA3 is involved in the regulation of T cell function, which is critical for the immune response. For example, studies have shown that SCARA3 can modulate the development and function of T cells, including their ability to recognize and respond to antigens.

In addition, SCARA3 has been shown to play a role in the regulation of cancer progression. For example, studies have shown that SCARA3 can promote the growth and survival of cancer cells. This may contribute to the development of cancer as a potential drug target.

Potential Biomarker

SCARA3 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because SCARA3 is expressed in various tissues and can be used as a marker for the presence of specific diseases.

For example, studies have shown that SCARA3 can be used as a biomarker for cancer. Researchers have shown that SCARA3 is often overexpressed in various tissues of cancer patients, including breast, ovarian, and prostate cancer. This may indicate that SCARA3 can be used as a potential biomarker for cancer.

In addition, SCARA3 has also been shown to be involved in the regulation of neurodegenerative diseases. For example, studies have shown that SCARA3 is involved in the regulation of neuroprotective enzymes, which are important for the treatment of neurodegenerative diseases.

In addition, SCARA3 has also been shown to be involved in the regulation of autoimmune disorders. For example, studies have shown that SCARA3 is involved in the regulation of the immune response, which is critical for the treatment of autoimmune disorders.

Conclusion

In conclusion, SCARA3 is a protein that is involved in the immune response and has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, SCARA3 is a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of SCARA3 in the immune response and its potential as a drug target and biomarker.

Protein Name: Scavenger Receptor Class A Member 3

Functions: Seems to protect cells by scavenging oxidative molecules or harmful products of oxidation

The "SCARA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets